Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers Post published:January 22, 2026 Post category:Psychedelic Bulletin/Pα+
Psychedelic Funding, Public Markets, and M&A in 2025 Post published:January 20, 2026 Post category:Analysis/Pα+
Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World Post published:January 19, 2026 Post category:2025 Year in Review/Opinions
The Psychedelic News Feed: January 12 – 18, 2026 Post published:January 19, 2026 Post category:Psychedelic News Feed Archive
Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next Post published:January 16, 2026 Post category:2025 Year in Review/Opinions
Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions Post published:January 15, 2026 Post category:2025 Year in Review/Analysis/News/Pα+
Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us Post published:January 14, 2026 Post category:2025 Year in Review/Opinions
The Psychedelic News Feed: January 05 – 11, 2026 Post published:January 13, 2026 Post category:Psychedelic News Feed Archive
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus Post published:January 8, 2026 Post category:Psychedelic Bulletin/Pα+
2025 Year in Review: Future(s) & Open Questions (Video) Post published:January 6, 2026 Post category:2025 Year in Review/Analysis/News/Pα+